Doximity (DOCS) Research & Development (2020 - 2026)

Doximity (DOCS) has 7 years of Research & Development data on file, last reported at $39.1 million in Q1 2026.

• Quarterly Research & Development rose 57.67% year-over-year to $39.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $130.7 million (up 40.48% YoY) and the FY2026 annual result came in at $130.7 million, up 40.48% from the prior year.
• Research & Development improved to $39.1 million in Q1 2026 per DOCS's latest filing, from $34.6 million in the prior quarter.
• Across five years, Research & Development topped out at $39.1 million in Q1 2026 and bottomed at $17.4 million in Q1 2022.
• The 5-year median for Research & Development is $21.9 million (2023), against an average of $23.7 million.
• The widest annual swing landed in 2024, when Research & Development fell 6.47%; it then jumped 57.67% in 2026.
• Tracing DOCS's Research & Development over 5 years: stood at $20.5 million in 2022, then dropped by 2.79% to $19.9 million in 2023, then grew by 12.41% to $22.4 million in 2024, then jumped by 54.3% to $34.6 million in 2025, then advanced by 13.04% to $39.1 million in 2026.
• Per Business Quant, the three latest DOCS Research & Development figures stand at $39.1 million (Q1 2026), $34.6 million (Q4 2025), and $30.2 million (Q3 2025).

Peer Comparison